메인으로

Research Status

  • home icon

PIPELINE

Research Status

With TOFPOMICS®, a technology development platform, ONCOBIX has a range of drug discovery pipelines for the 4th-generation NSCLC therapies, pulmonary fibrosis therapies, and pancreatic/lung cancer therapies, and we are further expanding our pipelines through continuous dedication to research.

- Objectives Per Task : Identify and discover new best-in-kinase drugs

Pipeline Indication Platform Discovery Development
Hit/lead compound Candidate compound Preclinical Phase I Phase II Phase III
In House Research
OBX02 Series

EGFR: Non-Small Cell Lung Cancer

Idiopathic/radiotherapy-induced pulmonary fibrosis

Glioblastoma

OBX10 Series

EGFR mediated EMT:
Idiopathic/radiotherapy-induced pulmonary fibrosis

OBX13 Series

ALK/ROS1: Non-Small Cell Lung Cancer

OBX09 Series

FAK: Lung cancer/pancreatic cancer

Joint Research
OBX08 Series

Non-Small Cell Lung Cancer

TOFPOMICS®

OBX16 Series

Immuno-oncology

OBX17 Series

Psoriasis

OBX18 Series

Glioblastoma

EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition; ALK, Anaplastic lymphoma kinase; ROS1, c-ros oncogene 1; FAK, focal adhesion kinase

Development Stage: Hit (Hit compound) => Lead (Lead compound) => Candidate (Candidate compound)

회원로그인

회원가입